drugset / Trial / NCT00079157
Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer
Phase 1
Completed
28 enrolled
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving a vaccine with Montanide ISA-51 and sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy when given together with Montanide ISA-51 and sargramostim in treating patients with stage IV breast cancer.
Timeline
- Start
- 2004-02
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | telomerase: 540-548 peptide vaccine | Vaccine | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |